Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Pacritinib [USAN:INN]
RN: 937272-79-2
UNII: G22N65IL3O
InChIKey: HWXVIOGONBBTBY-ONEGZZNKSA-N

Note

  • For treating lymphoma and myelofibrosis.

    NCI: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity. (NCI Thesaurus)

Molecular Weight

  • 472.5858
 

Classification Code

  • Antineoplastic Agents
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Pacritinib [USAN:INN]

Synonyms

  • Pacritinib
  • SB 1518
  • SB-1518
  • SB1518
  • UNII-G22N65IL3O

Systematic Name

  • 14,19-Dioxa-5,7,27-triazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-(2-(1-pyrrolidinyl)ethoxy)-, (16E)-

Registry Numbers

CAS Registry Number

  • 937272-79-2

FDA UNII

  • G22N65IL3O

Other Registry Number

  • 1138325-13-9

System Generated Number

  • 0937272792

Structure Descriptors

InChI

1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

InChIKey

HWXVIOGONBBTBY-ONEGZZNKSA-N

Smiles

c1cc2cc(c1)C3=N/C(=N\c4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5)/NC=C3